3rd Annual Global Summit on

GENITOURINARYO CTOBER 10-13 , 2019BANFF | CANADA

MALIGNANCIES

3rd Annual Global Summit on

MALIGNANCIES AGENDAGENITOURINARY

O CTOBER 10-13 , 2019BANFF | CANADA

Thursday, October 10, 20195:45 PM Welcome and Introductions

KEYNOTE ADDRESS6:00 PM GU Malignancies: Perspectives and a Peer Into

the Future

SETTING THE STAGE6:30 PM What are the Practice Changes in 2019 for

Advanced Prostate Cancer?6:45 PM What are the Practice Changes in 2019 for

Metastatic RCC?7:00 PM What are the Practice Changes in 2019 for

Bladder Cancer?7:15 PM Moving Forward with Immunotherapy in GU

Malignancies7:30 PM The Era of Personalized Therapy for GU Tumors7:45 PM DISCUSSION8:00 PM ADJOURN TO WELCOME RECEPTION

Friday, October 11, 20196:00 AM BREAKFAST

ADVANCES IN IMAGING AND DIAGNOSIS7:00 AM Blue Light Flexible Cystoscopy with

Hexaminolevulinate for Surveillance of Bladder Cancer

7:15 AM PET Imaging in Prostate Cancer7:30 AM Challenges with RCC Type 1 and Type 2

Pathology Diagnosis7:45 AM Subtyping RCC on Imaging - The Role of

Radiologist8:00 AM Modeling Cost Effectiveness of Biomarker Based

Approaches to Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

8:15 AM Biotech Showcase8:30 AM DISCUSSION

THE ROLE OF SURGERY IN GU MALIGNANCIES

9:00 Optimal Timing for Radical Cystectomy After Neoadjuvant Chemotherapy

9:15 Radical Prostatectomy in Metastatic Disease9:30 Discussion

10:00 BREAK

IMMUNOTHERAPY IN GU MALIGNANCIES10:15 AM Maximizing Clinical Response to Immune

Checkpoint Therapy in GU Malignancies10:30 AM Current Data and Future Trials for PD-1/PD-L1

Inhibitors for Bladder Cancer10:45 AM Is There a Future for Immunotherapy in Prostate

Cancer?11:15 AM Biotech Showcase11:30 AM DISCUSSION AND CASE STUDIES12:00 PM ADJOURN

CURRENT UNDERSTANDING OF TKI IN RCC5:00 PM How do we Optimize the Effectiveness of VEGF

Inhibitors?5:15 PM The Role of Sequencing in TKIs5:30 PM DISCUSSION

THE SPECTRUM OF METASTATIC DISEASE IN PROSTATE CANCER

5:45 PM Management of Metastatic Castrate-sensitive Prostate Cancer

6:00 PM Does Treating the Primary Make a Difference in Metastatic Disease?

6:15 PM DISCUSSION

LEARNING FROM GENOMICS AND BIOMARKERS

6:30 PM Emerging Biomarkers and Imaging Tests to Improve Prostate Cancer Diagnostics

6:45 PM Genetic Heterogeneity in Kidney Cancer7:00 PM Genomic Classification in Localized Disease:

How can it Improve Outcomes?7:15 PM Molecular Landscape of non-Muscle Invasive

Versus Muscle Invasive Bladder Cancer7:30 PM Utilizing Genomics for the Selection of Systemic

Therapy7:45 PM DISCUSSION8:15 PM ADJOURN

3rd Annual Global Summit on

MALIGNANCIES AGENDAGENITOURINARY

O CTOBER 10-13 , 2019BANFF | CANADA

Saturday, October 12, 20196:00 AM BREAKFAST

TARGETED THERAPY IN BLADDER CANCER7:00 AM Targeting FGFR and mTOR in Bladder Cancer7:15 AM Targeting DNA Repair Genes in Bladder Cancer7:30 AM Taking Advantage of Nectin-4 Expression in

Bladder Cancer with ADCs7:45 AM Updates in Management of Urothelial Cancer8:00 AM DISCUSSION

BLADDER PRESERVATION THERAPY8:15 AM Match Pair Analysis of Cystectomy Compared to

Tri-Modality Therapy8:30 AM Curative Treatments of Invasive Bladder Cancer

Using Combined Modality Therapy9:00 AM Combining Immunotherapy and Radiation

Therapy in Bladder Cancer9:15 AM DISCUSSION

TARGETING AR IN CRPC: A MAJOR THERAPEUTIC CHALLENGE

9:30 AM AR Agents in non-Metastatic CRPC9:45 AM Biologic Rationale for Next-generation AR

Inhibitors10:00 AM Approaches to Block Persistent AR Function in

Metastatic CRPC10:15 AM An Androgen Receptor PROTAC Degrader for

Prostate Cancer10:30 AM DISCUSSION10:45 AM BREAK

MOVING BEYOND HORMONE RECEPTORS IN PROSTATE CANCER10:55 AM PARP inhibitors in Prostate Cancer11:10 AM Alterations in AR Signaling in Prostate Cancer

Development and Progression11:25 AM CDK4/6 Inhibition as Novel Therapeutic Strategy

for Metastatic Prostate Cancer11:40 AM Biotech Showcase11:55 AM DISCUSSION AND CASE STUDIES12:30 PM ADJOURN

QUALITY OF LIFE AND OUTCOME CONSIDERATIONS FOR GU MALIGNANCIES

5:00 PM How can PRO Drive Drug Development and Standards of Care?

5:15 PM Emerging Quality of Life Trends with Early Use of Novel Antiandrogen Therapies in Advanced Prostate Cancer

5:30 PM Improving Real World Outcomes in Bladder Cancer

5:45 PM Integrating Lifestyle Changes and Exercise into Prostate Cancer Care

6:00 PM DISCUSSION

COMBINATION APPROACHES FOR IMMUNOTHERAPY

6:15 PM Combination Therapy Targeting CTLA-4 and PD-1/PD-L1: Risks and Benefits for RCC

6:30 PM Immunotherapy Combination Approaches with Chemotherapy and Targeted Therapies in Bladder Cancer

6:45 PM Biotech Showcase7:00 PM Biotech Showcase7:15 PM DISCUSSION

PRACTICAL CONSIDERATION FOR IMMUNOTHERAPY

7:30 PM Managing Immunotherapy Toxicity in Bladder Cancer

7:45 PM Treatment After Checkpoint Therapy, What do we do Post Immunotherapy?

8:00 PM DISCUSSION 8:15 PM ADJOURN

Sunday, October 13, 20196:00 AM BREAKFAST

ORAL ABSTRACTS7:00 AM Oral Abstract 17:15 AM Oral Abstract 27:30 AM Oral Abstract 37:45 AM Oral Abstract 48:00 AM Oral Abstract 58:15 AM Oral Abstract 68:30 AM MEETING CONCLUDES

3rd Annual Global Summit on

GENITOURINARYMALIGNANCIES

For more imformation visit omionc.com